ArticleJournal of chemical information and modeling2025
Toward Assay-Aware Bioactivity Model(er)s: Getting a Grip on Biological Context.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL.Journal of cheminformatics · 2026Article
- Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context.Proceedings of the Conference on Empirical Methods in Natural Language Processing. Conference on Empirical Methods in Natural Language Processing · 2025Article
- Article
- In Search of Beautiful Molecules: A Perspective on Generative Modeling for Drug Design.Journal of chemical information and modeling · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-ligand interaction prediction with proteochemometric (PCM) models can provide valuable insights during early drug discovery and chemical safety assessment. These models have benefitted from the large amount of data available in bioactivity databases. However, an issue that is often overlooked when using this data is the broad diversity in the biological assays present. The effect of small molecules on a protein can be measured in various ways, and this can influence the outcome. Yet, currently there is a lack of standardized, specific assay metadata, while this could help increase understanding of the origin of data points, improve data curation, and lead to better models that are both more accurate and make predictions specific to the readout of interest. To make use of the existing information on the biological context, we set out to create and validate multiple assay descriptors and test their use in protein-ligand interaction models. Dimensionality reduction of embedded free text assay descriptions from ChEMBL showed that text embeddings capture relevant features. Additionally, clustering of these embedded descriptions groups the assays in a way that enriches purity, matches manually categorized assays, and yields sensible topic describing words. From ligand-protein combinations with multiple measurements, it becomes apparent that the deviation between different measurements in general is higher than the deviation of measurements within assay categories, with a logarithmic mean absolute deviation of 0.83 and 0.66, respectively. Incorporating this biological context into the PCM models in the form of BioBERT-based embeddings improved the average
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.